Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Colorectal Cancer: Regorafenib Patient Selection and Dosing

July 12th 2016

Goals of Therapy in Refractory Colorectal Cancer

July 12th 2016

Decisions in Colorectal Cancer Maintenance Therapy and Sequencing

July 12th 2016

Right- Versus Left-Sided Colorectal Tumors and Survival

July 12th 2016

Colorectal Cancer: Choosing a Biologic

July 12th 2016

Neoadjuvant and Adjuvant Therapy in Metastatic Colorectal Cancer

July 12th 2016

Goals of Systemic Therapy in Colorectal Cancer

July 12th 2016

Multidisciplinary Approaches in Metastatic Colorectal Cancer

July 12th 2016

Optimizing Care in Metastatic Colorectal Cancer

July 12th 2016

Finding Actionable Biomarkers in Colorectal Cancer

July 12th 2016

Liquid- Vs Tissue-Based Testing in Colorectal Cancer

July 12th 2016

An Update on Molecular Testing in Colorectal Cancer

July 12th 2016

Dr. Overman on Implications of Tumor Location Data for Patients With mCRC

July 11th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.

Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC

July 8th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

First-Line Cetuximab Combo Validated in RAS Wild-Type Colorectal Cancer

July 3rd 2016

The addition of cetuximab to standard FOLFOX-4 chemotherapy in the first-line treatment of patients with RAS wild-type metastatic colorectal cancer significantly improved survival outcomes.

MABp1 Improves Symptoms in Phase III CRC Study

July 3rd 2016

MABp1, a novel anti–interleukin 1-alpha antibody, was safe, well-tolerated, and demonstrated a significant impact on symptoms compared with placebo for patients with advanced colorectal cancer.

SIRT Improves Depth of Response in mCRC Patients With Liver Mets

July 1st 2016

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.

Dr. Berger on the Significance of the Cologuard Screening Test

July 1st 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses the significance and benefits of the Cologuard screening test for colorectal cancer.

Dr. Yurgelun on Susceptibility Gene Mutations in CRC

June 30th 2016

Daniel Sargent on International Collaboration for Colon Cancer Research

June 30th 2016

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.